NCT02668926View on ClinicalTrials.gov

Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2016

Conditions
Healthy
Interventions
DRUG

Lisdexamfetamine, d-amphetamine, Placebo

Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.

DRUG

d-amphetamine, Placebo, Lisdexamfetamine

Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.

DRUG

Placebo, Lisdexamfetamine, d-amphetamine

Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT02668926 - Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine. | Biotech Hunter | Biotech Hunter